Serum hsa_circ_0087776 as a new oncologic marker for the joint diagnosis of multiple myeloma

Abstract

Multiple myeloma (MM) is a hematologic malignancy caused by abnormal proliferation of bone marrow plasma cells, which lacks diagnostic markers and has a general prognosis. At present, the understanding of its pathogenesis provides the basis for the combined diagnosis and new targeted therapy of the disease. In this study, quantitative real-time PCR was used to detect 136 MM patients and 74 healthy controls, and the clinical application value of hsa_circ_0087776 as a new tumor marker and combined diagnosis was evaluated. The results showed that the expression of hsa_circ_0087776 was significantly lower in serum of MM patients (P-value < 0.0001), and the expression was consistent in MM cells. In the analysis of clinicopathological parameters, it was found that there were significant statistical differences with MM stage and renal injury. In addition, it significantly increased the sensitivity with ALB, β₂-MG joint diagnosis, to provide a basis for diagnosis, improve the prognosis of the disease, improve the survival of patients and quality of life. These studies suggest that hsa_circ_0087776 can be used as a new oncology marker for the combined diagnosis of MM.Impact statement: Various evidences have shown that the role of circRNA in the occurrence and development of diseases is potentially unknown and untapped. Therefore, it has a broad prospect to find circRNA specifically expressed in MM patients for combined diagnosis and targeted therapy of MM. However, MM lacks such specific tumor markers. Therefore, the discovery of new specific tumor markers for combined diagnosis is an important milestone in the development of medical history. In the research, we founded hsa_circ_0087776 can be used as a new oncology marker for combined diagnosis of MM.

Keywords: Multiple myeloma; biomarker; diagnosis; hsa_circ_0087776; quantitative real-time PCR; serum.

Figure 1.

Methodological evaluation of hsa _circ _0087776. (a) The hsa_circ_0087776 standard curve. (b) The 18s standard curve. (c, d) Stability of hsa_circ_0087776 and 18s in room temperature incubation and repeated freeze-thaw

Figure 2.

Methodological evaluation of hsa _circ _0087776. (a) Single peak specificity of hsa _circ _0087776 and 18s dissolution and amplification curves. (b) The specificity of hsa _circ _0087776 and 18s was verified by agarose gel electrophoresis. (c) Sequencing results of hsa _circ _0087776 and 18s

Figure 3.

Detection of hsa _circ _0087776 relative expression in serum. (a) Hsa_circ-0087776 and 18s mRNA expression after treatment with RNase R. (b) Differential expression of hsa-circ-0087776 in serum of MM patients. (c) Differential expression of hsa-circ-0087776 in MM cell lines. (*P < 0.05; **P < 0.01; ***P < 0.001)

Figure 4.

Evaluation of combined diagnostic efficacy of hsa _circ _0087776. (a) The ROC curve of serum hsa _circ _0087776. (b) The ROC curve of ALB. (c) The ROC curve of β2-MG. (d) By contrast, the diagnostic efficacy of serum hsa _circ _0087776 is remarkable

Figure 5.

Changes in the expression of hsa_circ_0087776 before and after treatment (P = 0.0111)